Exchange: NASDAQ·Updated 04:10 PM EDT
IART logo

IARTIntegra Lifesciences Holdings Corp

$18.79
$0.40
(2.17%)
Today
Closed $18.79
$0.00
(0.00%)
After Hours
EarningsJul 30
Mkt Cap$1.46B
Vol951,870.00
News
all
press releases
Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?
ZBH is banking on knee growth, robotics and restructuring to drive results, but can macro pressures and competition limit the upside?
Zacks
News Placeholder
More News
News Placeholder
Should You Continue to Hold OMCL Stock in Your Portfolio Now?
Omnicell is advancing its autonomous pharmacy vision and expanding SaaS offerings, but tariffs and fierce competition could test its growth path.
Zacks
News Placeholder
Does NVST Stock Still Deserve a Place in Your Portfolio?
Envista executes on growth priorities with new products, acquisitions and global expansion, but macro, tariff and currency headwinds remain in focus.
Zacks
News Placeholder
Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?
ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.
Zacks
News Placeholder
Here's Why Integra LifeSciences (IART) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Integra (IART) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Integra (IART) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks
News Placeholder
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.
Zacks
News Placeholder
What's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?
OMCL's autonomous pharmacy strategy, SaaS growth and global expansion boost shares. Can rising costs and tariffs slow the momentum?
Zacks
News Placeholder
Does TNDM Stock Still Deserve a Place in Your Portfolio?
Tandem Diabetes targets diabetes market growth with a new reimbursement model and strong liquidity. Can it overcome macro and pump execution risks?
Zacks
News Placeholder
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
<
1
2
...
>

Advertisement|Remove ads.